The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index; 9 of the 19 sources its claims cite were checked for support.
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Open accessAbstract
Advanced age is the main risk factor for most chronic diseases and functional deficits in humans, but the fundamental mechanisms that drive ageing remain largely unknown, impeding the development of interventions that might delay or prevent age-related disorders and maximize healthy lifespan. Cellular senescence, which halts the proliferation of damaged or dysfunctional cells, is an important mechanism to constrain the malignant progression of tumour cells. Senescent cells accumulate in various tissues and organs with ageing and have been hypothesized to disrupt tissue structure and function because of the components they secrete. However, whether senescent cells are causally implicated in age-related dysfunction and whether their removal is beneficial has remained unknown. To address these fundamental questions, we made use of a biomarker for senescence, p16(Ink4a), to design a novel transgene, INK-ATTAC, for inducible elimination of p16(Ink4a)-positive senescent cells upon administration of a drug. Here we show that in the BubR1 progeroid mouse background, INK-ATTAC removes p16(Ink4a)-positive senescent cells upon drug treatment. In tissues--such as adipose tissue, skeletal muscle and eye--in which p16(Ink4a) contributes to the acquisition of age-related pathologies, life-long removal of p16(Ink4a)-expressing cells delayed onset of these phenotypes. Furthermore, late-life clearance attenuated progression of already established age-related disorders. These data indicate that cellular senescence is causally implicated in generating age-related phenotypes and that removal of senescent cells can prevent or delay tissue dysfunction and extend healthspan.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
The paper describes INK-ATTAC, a transgenic mouse system that allows drug-inducible removal of p16Ink4a-positive senescent cells. In a BubR1 hypomorphic progeroid background, clearing these cells delayed or slowed several age-related phenotypes in adipose tissue, skeletal muscle, and eye, supporting a causal role for cellular senescence in age-related dysfunction.
Key findings
- INK-ATTAC expression overlapped with endogenous p16Ink4a: GFP+ cells from aged BubR1H/H;INK-ATTAC adipose tissue had higher p16Ink4a and other senescence markers than GFP− cells, and AP20187 killed most rosiglitazone-induced senescent bone marrow cells within 48 h in vitro.
- Life-long AP20187 treatment from 3 weeks of age in BubR1H/H;INK-ATTAC lines 3 and 5 delayed lordokyphosis and cataracts, increased muscle fibre diameter, improved treadmill exercise duration/distance/work, and prevented adipose tissue loss; these delays were absent in BubR1H/H mice without the transgene.
- Late-life treatment starting at 5 months and assessed at 10 months improved muscle fibre size and exercise performance and increased fat depots and adipocyte size, but cataracts that had already matured remained unchanged; the effects reflected slowed progression rather than reversal of ageing.
- p16Ink4a-independent phenotypes such as cardiac arrhythmias and arterial wall stiffening were not attenuated, and overall survival was not substantially extended, likely because cardiac failure is the main cause of death in this model. No overt side effects were observed in WT;INK-ATTAC mice treated until 8 months.
Methods
- The INK-ATTAC construct used a 2,617-bp murine p16Ink4a promoter fragment to drive FKBP–Casp8, with an IRES-EGFP reporter; nine transgenic founder lines were generated and bred onto the BubR1 hypomorphic background, with lines 3 and 5 selected for study.
- AP20187 was injected intraperitoneally every 3 days at 0.2 μg/g body weight from weaning (life-long) or from 5 months (late-life); phenotypes were assessed by lordokyphosis and cataract checks, muscle and fat histology, DEXA, treadmill exercise, BrdU incorporation, SA-β-Gal staining, qRT–PCR, and FACS.
- In vitro, bone marrow cells were treated with 1 μM rosiglitazone for 5 days and then 10 nM AP20187 for 48 h; MEFs were induced to senesce by serial passaging (12–15 passages) or H-ras expression, sorted into GFP+ and GFP− populations, and analysed. Statistical comparisons used two-tailed unpaired t tests and log-rank tests.
Limitations
- The paper states that no universal marker expressed solely in senescent cells has been identified, and the approach relies on p16Ink4a promoter activity and two transgenic lines.
- The paper notes that overall survival was not substantially extended, probably because cardiac failure dominates mortality in BubR1H/H mice; p16Ink4a-independent pathologies were unaffected, and mature cataracts did not improve with late-life clearance.
- Evident from the text: the findings are in a progeroid BubR1 hypomorphic mouse model rather than natural ageing, some measurements were performed in female mice, and absence of overt side effects was only tested in WT;INK-ATTAC mice up to 8 months.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
31 Own result · 7 No full text of the sources · 4 Partly supported · 4 Own interpretation · 3 Supported · 2 No basis given · 1 Supported so far · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Although a universal marker that is solely expressed in senescent cells has not been identified, most senescent cells seem to express p16Ink4a, a cyclin-dependent kinase inhibitor and tumour suppressor that enforces growth arrest by activating Rb5,7.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Supportedcites [5] Rodier, F. & Campisi, J. Four faces of cellular senescence. J. Cell Biol. 192, 547–556 (2011) source
In “What defines a senescent cell?” the paper explicitly states that most senescent cells express p16INK4a. The same section notes that no identified marker is entirely specific to senescence, consistent with the citing sentence’s qualification. (LLM, conf=0.95)
- Not checked — no full text of the sourcecites [7] Kim, W. Y. & Sharpless, N. E. The regulation of INK4/ARF in cancer and aging. Cell 127, 265–275 (2006) source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, our data indicate that acquisition of the senescence-associated secretory phenotype (SASP), which enables cells to secrete a variety of growth factors, cytokines and proteases4, contributes to age-related tissue dysfunction.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Supportedcites [4] Coppé, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, e301 (2008) source
The citation is attached to the description of the SASP, not to the citing authors’ conclusion about age-related tissue dysfunction. The source paper’s Discussion describes the SASP as a secretory phenotype and reports high levels of secreted inflammatory cytokines and growth factors; it also suggests that chronic secretion may disrupt tissue function. (LLM, conf=0.87)
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“rosiglitazone, a drug that can induce cellular senescence and p16Ink4a expression through activation of PPARγ16.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Partly supportedcites [16] Gan, Q. et al. PPARγ accelerates cellular senescence by inducing p16INK4α expression in human diploid fibroblasts. J. Cell Sci. 121, 2235–2245 (2008) sourceExperimental — accuracy not yet measured
The “PPARγ-mediated regulation of p16INK4α expression” section reports that PPARγ overexpression or troglitazone treatment increased p16 protein in human fibroblasts; the RNA-interference section links PPARγ-agonist effects to senescence. The paper’s treatment passages name troglitazone and pioglitazone, not rosiglitazone, so they do not establish the claim for that specific drug. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Senescent cells accumulate in various tissues and organs with ageing3”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Supportedcites [3] Campisi, J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 120, 513–522 (2005) source
In the “Cellular Senescence and Aging” passage, the paper states that cells with characteristics of senescence accumulate with age in multiple tissues in humans and rodents. This supports the citing sentence’s claim. (LLM, conf=0.94)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We replaced the Fabp4 promoter with a 2,617-bp fragment of the p16Ink4a gene promoter that is transcriptionally active in senescent, but not non-senescent cells (Fig. 1a)9.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Partly supportedcites [9] Wang, W., Wu, J., Zhang, Z. & Tong, T. Characterization of regulatory elements on the promoter region of p16INK4a that contribute to overexpression of p16 in senescent fibroblasts. J. Biol. Chem. 276, 48655–48661 (2001) sourceExperimental — accuracy not yet measured
The Discussion reports that the tested p16INK4a promoter fragments were 5–7 times more active in senescent than in young fibroblasts, supporting senescence-associated activity. It does not identify a 2,617-bp fragment, and its measurements of promoter activity in young cells do not support the claim that the promoter is inactive in non-senescent cells. (LLM, conf=0.84)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Skeletal muscle and eye had a similar reduction in senescence indicators (Fig. 3c, d and Supplementary Fig. 6b, c).”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Age-related phenotypes of BubR1H/H mice that arise in a p16Ink4a-independent fashion, such as cardiac arrhythmias and arterial wall stiffening14, were not attenuated in AP20187-treated BubR1H/H;INK-ATTAC mice (Supplementary Fig. 5a, b).”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Not checked — no full text of the sourcecites [14] Matsumoto, T. et al. Aging-associated vascular phenotype in mutant mice with low levels of BubR1. Stroke 38, 1050–1056 (2007) source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The above age-related phenotypes were not delayed upon AP20187 treatment of BubR1H/H mice lacking INK-ATTAC (Fig. 2b and Supplementary Fig. 4).”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that the vast majority of cells from both transgenic lines were either dead or in the process of dying 48 h after adding AP20187 (Fig. 2a).”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The IAT of AP20187-treated BubR1H/H;INK-ATTAC mice showed a marked decrease in SA-β-Gal staining compared with the IAT of untreated counterparts (Fig. 3a).”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Probably not a substantial claim. 4
- It may state two separate claims as one. 8
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, the expression of p16Ink4a is known to increase with ageing in several rodent and human tissues8.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Partly supportedcites [8] Krishnamurthy, J. et al. Ink4a/Arf expression is a biomarker of aging. J. Clin. Invest. 114, 1299–1307 (2004) sourceExperimental — accuracy not yet measured
The 'Expression of Ink4a/Arf in vivo' section reports increased p16INK4a expression with age across many mouse and rat tissues. Table 1 compares those findings with published human tissue staining, but does not show age-related increases across several human tissues; the References name evidence for aging human kidney specifically. The claim's extension to several human tissues is therefore not established by this copy (no page numbers available). (LLM, conf=0.86)
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“senescence-associated secretory phenotype (SASP), which enables cells to secrete a variety of growth factors, cytokines and proteases4”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Partly supportedcites [4] Coppé, J. P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, e301 (2008) sourceExperimental — accuracy not yet measured
In the Results section on senescent fibroblasts (page unavailable), the paper identifies cytokines and growth factors as SASP components and reports increased secretion of SASP proteins. The passages in our copy do not identify secreted proteases as SASP components, so that part of the claim is unsupported. (LLM, conf=0.84)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Cellular senescence, which halts the proliferation of damaged or dysfunctional cells, is an important mechanism to constrain the malignant progression of tumour cells1,2.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Supportedcites [1] Campisi, J. Cellular senescence: putting the paradoxes in perspective. Curr. Opin. Genet. Dev. 21, 107–112 (2011) source
In “Senescent cells – in culture and in vivo,” the paper describes an essentially irreversible growth arrest in response to stresses including DNA damage and dysfunctional telomeres. In “Cellular senescence and tumor suppression,” it says that this growth arrest suppresses malignant tumorigenesis and that dismantling the senescence response accelerates progression from premalignant lesions to malignant tumors. (LLM, conf=0.93)
- Supportedcites [2] Kuilman, T., Michaloglou, C., Mooi, W. J. & Peeper, D. S. The essence of senescence. Genes Dev. 24, 2463–2479 (2010) source
In “Replicative cellular senescence,” the paper says that sufficiently severe DNA damage can lead to senescence rather than continued proliferation. “Cellular senescence as a pathophysiological phenomenon” describes oncogene-induced proliferation arrest as a defense against tumor formation, and “Secreted factors in senescence” says senescence limits the expansion of early malignant cells. Page numbers are not available in our copy. (LLM, conf=0.91)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Importantly, late-life treated animals had increased mean muscle fibre diameters and showed improved performance in treadmill exercise tests (Fig. 4a, b).”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together, these data indicate that senescent cells were cleared from tissues and that this delays acquisition of age-related dysfunction in BubR1 hypomorphic mice.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Furthermore, most fat depots of these animals were enlarged and adipocyte cell size and subdermal adipose layer thickness were significantly increased (Fig. 4c–e).”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“treadmill exercise tests revealed that duration of exercise, distance travelled and overall amount of work performed were all significantly increased in the animals treated with AP20187 (Fig. 2e), indicating preservation of muscle function.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We observed GFP fluorescence in two of these strains, BubR1H/H;INK-ATTAC-3 and -5 (Fig. 1b and Supplementary Fig. 1a).”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Skeletal muscle and lens tissue of aged BubR1H/H;INK-ATTAC mice are SA-β-Gal negative (data not shown), but both these tissues expressed other markers of senescence (Fig. 1f and Supplementary Fig. 3a).”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and that removal of senescent cells can prevent or delay tissue dysfunction and extend healthspan.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“AP20187, a synthetic drug that induces dimerization of a membrane-bound myristoylated FK506-binding-protein–caspase 8 (FKBP–Casp8) fusion protein expressed specifically in adipocytes via the minimal Fabp4 promoter6.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Not checked — no full text of the sourcecites [6] Pajvani, U. B. et al. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nature Med. 11, 797–803 (2005) source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“BubR1H/H mice have a markedly shortened lifespan and exhibit a variety of age-related phenotypes, including infertility, lordokyphosis, sarcopenia, cataracts, fat loss, cardiac arrhythmias, arterial wall stiffening, impaired wound healing and dermal thinning12–14.”
§ Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders > Abstract
What the sources say
- Not checked — no full text of the sourcecites [12] Baker, D. J. et al. BubR1 insufficiency causes early onset of aging-associated phenotypes and infertility in mice. Nature Genet. 36, 744–749 (2004) source
- Not checked — no full text of the sourcecites [13] Hartman, T. K., Wengenack, T. M., Poduslo, J. F. & van Deursen, J. M. Mutant mice with small amounts of BubR1 display accelerated age-related gliosis. Neurobiol. Aging 28, 921–927 (2007) source
- Not checked — no full text of the sourcecites [14] Matsumoto, T. et al. Aging-associated vascular phenotype in mutant mice with low levels of BubR1. Stroke 38, 1050–1056 (2007) source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The authors state this as an assumption.
Cardiac failure is the main cause of death in BubR1H/H mice.
“Cardiac failure is presumably the main cause of death in BubR1H/H mice (data not shown)”
The paper relies on this without support.
Before this study, it was unknown whether senescent cells are causally implicated in age-related dysfunction and whether removing them is beneficial.
“However, whether senescent cells are causally implicated in age-related dysfunction and whether their removal is beneficial has remained unknown.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Reducing highly p16Ink4a+-expressing cells, some of which are senescent, in INK-ATTAC transgenic mice starting from mid-adulthood (age 12 months) reportedly extends median lifespan49.”
From Senolytics improve physical function and increase lifespan in old age (2018) · cites this paper as [49]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ablating p16+ cells in these mice suppresses age-related disease, extending the health span of two independent strains of transgenic mice: INK-ATTAC and p16-3MR (see Supplemental Figure 1 for a description of the models) (8–10).”
From Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This BubR1H/H progeria model has accelerated and elevated superphysiologic levels of cellular senescence due to chromosome missegregation as well as increasing aneuploidy (8, 80).”
From Senolytic Drugs: Reducing Senescent Cell Viability to Extend Health Span (2021) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, many immune cell types and subtypes develop a senescence-like state with increased expression of p16, p21, and SASP factors92,93.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [93]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, adaptive immune function can be improved by short-term treatment with rapamycin95, which reduces the markers of senescence and SASP in PBMCs93.”
From Guidelines for minimal information on cellular senescence experimentation in vivo (2024) · cites this paper as [93]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The healthspan of mice is enhanced by killing senescent cells using a transgenic suicide gene.”
From The Achilles' heel of senescent cells: from transcriptome to senolytic drugs (2015) · cites this paper as Baker et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Both recent intervention studies18 and our correlative data presented here strongly underscore the importance of cell senescence for determination of ageing rate and lifespan in mammals.”
From Chronic inflammation induces telomere dysfunction and accelerates ageing in mice (2014) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In pre-clinical aging models, accumulation of senescent cells is associated with multiple chronic diseases and disorders, geriatric syndromes, multi-morbidity, and accelerated aging phenotypes.”
From Reducing Senescent Cell Burden in Aging and Disease (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Compared to vehicle-treated mice, skeletal muscle of life-long AP20187-treated mice exhibited significantly lower expression of transgene elements (CASP8, EGFP) and senescence markers, including p16, p21, p19, Pai1, Il6, Mmp3, and Mmp13.”
From Skeletal muscle aging, cellular senescence, and senotherapeutics: current knowledge and future directions (2021) · cites this paper as Baker et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Transgenic mouse lines where senescent cells can be cleared by a genetic construct and commercially available senolytic drugs should also be considered as sensitivity to senolytic methods is one of the strongest lines of evidence currently used in the literature [167,172–174].”
From Untangling senescent and damage‐associated microglia in the aging and diseased brain (2023) · cites this paper as [172]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“depletion of cells expressing the senescence marker cyclin-dependent kinase inhibitor p16INK4A in genetically modified mice prolongs median lifespan and improves overall health (Baker et al. 2016; Farr et al. 2017; Baker et al. 2011; Jeon et al. 2017; Abdul-Aziz et al. 2019; Kim et al. 2019; Patil et al. 2019; Xu et al. 2015; Roos et al. 2016; Baar et al. 2017)”
From Single-cell RNA sequencing identifies senescent cerebromicrovascular endothelial cells in the aged mouse brain (2020) · cites this paper as Baker et al. 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Treatments to target and kill senescent cells, like senolytics, have shown promising results in extending lifespans and ameliorating various diseases.12,13”
From Single-cell senescence identification reveals senescence heterogeneity, trajectory, and modulators (2024) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mutant mice with premature aging due to extensive and persistent damage, present dramatic levels of senescence and their progeroid phenotypes are ameliorated by elimination of p16Ink4a or p53”
From The Hallmarks of Aging (2013) · cites this paper as Baker et al., 2011
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Removal of the p16Ink4a-positive senescent cells, for instance, using a suicide gene under the regulation of the Cdkn2a promoter has been shown to attenuate progression of age-related decline and preserve cognitive function in both an accelerated aging AD mouse model and a tauopathy mouse model (Baker et al., 2011; Bussian et al., 2018).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Baker et al., 2011
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Consistent with this idea is the observation that interference with senescent cell accumulation in BubR1 progeroid mice delays several aging-associated disorders that these animals develop 4 , 5 .”
From Naturally occurring p16Ink4a-positive cells shorten healthy lifespan (2016) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Although drug-treated BubR1H/H;INK-ATTAC mice did not live longer, they were remarkably protected from several other age-related pathologies, including cataracts, sarcopenia, and loss of subcutaneous fat (128).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“This study provided the first direct evidence that senescent cells can, at least in a premature aging mouse model, drive degenerative age-related pathology.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“The idea that senescent cells can drive age-related pathology recently received substantial support from a transgenic mouse model in which senescent cells could be eliminated by administering a drug (128).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [128]
The cited source says what the claim attributes to it.
In the citing paper
“treatment of BubR1 hypomorphic mice harbouring the INK-ATTAC transgene to remove p16-expressing cells beginning at weaning age attenuated the accumulation of senescent cells and premature ageing in skeletal muscle, eye and adipose tissue11”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Removal of SnCs delays several pathologies7–9 and increases healthy lifespan8.”
From Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment (2017) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“the previously reported INK-ATTAC transgenic mouse model, which expresses the FK506 binding protein–caspase-8 fusion protein under the control of the p16INK4a promoter7,8.”
From Local clearance of senescent cells attenuates the development of post-traumatic osteoarthritis and creates a pro-regenerative environment (2017) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“Earlier we have shown that, in BubR1 progeroid mice, ATTAC ablates p16 Ink4a -positive senescent cells upon administration of AP20187 (AP), a dimerizer that activates FKBP-fused Casp8 4 .”
From Naturally occurring p16Ink4a-positive cells shorten healthy lifespan (2016) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Selective removal of p16 INK4A+ cells from BubR1 H/H INK-ATTAC mice delays kyphosis, cataracts, and muscle atrophy”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Baker et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“but it does not delay cardiac arrhythmias and arterial wall stiffening nor does it extend lifespan”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Baker et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“the demonstration that ablation of p16 INK4A expressing cells slowed age-related declines in progeroid BubR1 H/H mice”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Baker et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“provided the first evidence that senescent cells are causal for certain aging phenotypes”
From Cellular Senescence: Defining a Path Forward (2019) · cites this paper as Baker et al., 2011
The cited source says what the claim attributes to it.
In the citing paper
“Models of accelerated cellular senescence show premature ageing and increased incidence of age-related pathologies, suggesting that accumulating senescent cells contributes to ageing-related functional compromise and predisposes to age-related disease [38].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“Using the Ink-Attac mouse model, in which a drug, AP20187 (AP), induces apoptosis through dimerization of FKBP-fused caspase 8, we previously discovered that clearance of p16-expressing cells improves parameters of physical health and function in progeroid mice31.”
From Cellular senescence mediates fibrotic pulmonary disease (2017) · cites this paper as [31]
The cited source says what the claim attributes to it.
In the citing paper
“Clearance of senescent cells is also beneficial for age-associated disorders 39 .”
From A complex secretory program orchestrated by the inflammasome controls paracrine senescence (2013) · cites this paper as [39]
The cited source says what the claim attributes to it.
In the citing paper
“elimination of senescent cells in an experimental progeria model delays age-related pathologies”
From The Hallmarks of Aging (2013) · cites this paper as Baker et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Longer term treatments (from 20 to 26 months of age) were effective at opposing several known phenotypes of aging: macrophage infiltration of tissues, a hallmark of chronic inflammation23,25, glomerulosclerosis of the kidney26 and skeletal muscle atrophy27 (Fig. 4e).”
From L1 drives IFN in senescent cells and promotes age-associated inflammation (2019) · cites this paper as [27]
Experimental — accuracy not yet measuredIn the citing paper
“Seminal discoveries, first by Hayflick and Moorehead, and lately by Baker et al., concretized cellular senescence as a major driver of aging with the age-associated accumulation of senescent cells”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Baker et al. 2011
In the citing paper
“and attenuation of age-related tissue dysfunction after their removal, even late in life (Hayflick and Moorhead 1961, Baker et al. 2011).”
From Benefits of Metformin in Attenuating the Hallmarks of Aging (2020) · cites this paper as Baker et al. 2011
In the citing paper
“Of note, we and our colleagues recently identified a possibly causal link between cellular senescence and aging phenotypes by showing that the clearance of senescent cells in a mouse progeroid model in vivo can delay age-related tissue dysfunction, including cataract formation, lipodystrophy, and lordokyphosis (7).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [7]
In the citing paper
“Experiments in progeroid INK-ATTAC;BubR1H/H mice showed that senescent cell clearance could reverse age-related lipodystrophy.”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [7]
In the citing paper
“Current methods for assessing senescent cell burden in vivo are at the tissue level, either by quantification of senescent cells through methods such as immunohistochemistry for markers including heterochromatin foci, p16 expression, SA-βgal activity, or screening for transgenic labels such as the p16INK4A promoter-driven GFP in the INK-ATTAC mouse (7).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [7]
In the citing paper
“The development of transgenic mice from which senescent cells can be selectively cleared allowed the demonstration of senescent cells' causal role in disease (7).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [7]
In the citing paper
“Removal of senescent cells can attenuate age-related tissue dysfunction and extend health span.”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Baker et al., 2011
In the citing paper
“selective elimination of senescent cells can prevent or delay age-related tissue dysfunction to extend life span and improve health span (Baker et al., 2011; Xu et al., 2015a; Baker et al., 2016; Hashimoto et al., 2016; Zhao et al., 2018).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Baker et al., 2011
In the citing paper
“Recently, attention has focused on the effect of senescence in vivo where purging p16-positive senescent cells in transgenic mice increased mean lifespan as well as aspects of healthspan65.”
From The central role of DNA damage in the ageing process (2021) · cites this paper as [65]
In the citing paper
“Another key feature of cellular senescence is the senescence-associated secretory phenotype (SASP), which is dependent on p38MAPK (p38 mitogen-activated protein kinases), NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells), cGAS(cyclic GMP-AMP synthase)/STING(stimulator of IFN genes), NOTCH and mTORmammalian target of rapamycin) signalling [38,39,40,41,42].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [38]
In the citing paper
“Models of accelerated cellular senescence show premature ageing and increased incidence of age-related pathologies, suggesting that accumulating senescent cells contributes to ageing-related functional compromise and predisposes to age-related disease [38].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [38]
In the citing paper
“Increased levels of p16INK4a have been documented in aged and stressed tissues, compared to younger, healthy tissues, whereas the removal of p16INK4a-expressing senescent cells in mice prevented or delayed tissue dysfunction and age-related disorders [38,80].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [38]
In the citing paper
“progeroid models have provided in vivo experimental data of accelerated ageing-related degenerative pathologies.”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [38]
In the citing paper
“In addition, experimental senolysis ameliorated ageing-related pathologies [38].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [38]
In the citing paper
“Lifelong elimination of p16INK4A cells substantially delayed age-related disease, whereas late life elimination of p16INK4A cells attenuated these age-related pathologies [38]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [38]
In the citing paper
“robust in vivo proof of the causative involvement of senescent cells in aging and in particular age-related diseases10,11.”
From Identification and characterization of Cardiac Glycosides as senolytic compounds (2019) · cites this paper as [11]
In the citing paper
“clearing senescent cells from progeroid or naturally aging mice improves healthspan 10, increases lifespan 12 and benefits an array of pathologies”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [10]
In the citing paper
“Genetic and pharmacological strategies have demonstrated the benefits of eliminating senescent cells in the context of aging and disease 10,12,51.”
From Cardiac glycosides are broad-spectrum senolytics (2019) · cites this paper as [10]
In the citing paper
“To circumvent this problem, two similar yet unique mouse models have been developed to detect and eliminate senescent cells.”
From Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives (2018) · cites this paper as [29]
In the citing paper
“Using mouse models, elimination of these cells, through either genetic means or senolytic therapies, has largely shown beneficial impacts, irrespective of the disease or condition investigated (29-31, 99, 100).”
From Cellular senescence in brain aging and neurodegenerative diseases: evidence and perspectives (2018) · cites this paper as [29]
In the citing paper
“In mice, the clearance of p16INK4A-positive cells extends lifespan and slows the emergence of ageing phenotypes and age-related functional deterioration of organs and tissues111,112.”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [111]
In the citing paper
“It is thus not surprising that senescent cell burden is a good predictor of animal lifespan.94,95”
From Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis (2020) · cites this paper as [94]
In the citing paper
“the clearance of senescent cells by either genetic engineering or the administration of senolytic drugs has been associated with reduced circulating levels of pro-inflammatory markers, increased lifespan, and delayed frailty-related phenotypes in mice”
From Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty (2018) · cites this paper as [111]
In the citing paper
“A cohort of aged INK-ATTAC transgenic mice, in which cells with high INK4a promoter activity, which is indicative of senescence, can be forced to undergo apoptosis138,139, exhibited increased resilience to pathogens, including the mouse hepatitis virus (MHV, a mouse β-coronavirus), when p16INK4a-high senescent cells were subjected to ATTAC-dependent depletion27.”
From COVID-19 and cellular senescence (2023) · cites this paper as [138]
In the citing paper
“Elimination of senescent cells by suicide gene-mediated ablation of p16Ink4a-expressing senescent cells in INK-ATTAC mice has resulted in significant improvements in healthspan and lifespan”
From Telomeres and cell senescence—size matters not (2017) · cites this paper as Baker et al., 2011
In the citing paper
“suggesting that senescent cells are drivers of ageing (Baker et al., 2011, Baker et al., 2016).”
From Telomeres and cell senescence—size matters not (2017) · cites this paper as Baker et al., 2011
In the citing paper
“Elimination of senescent cells may therefore allow better recovery of tissues, consistent with the finding that senescent cell elimination via transgenic techniques improves aging‐associated phenotypes”
From p21 maintains senescent cell viability under persistent DNA damage response by restraining JNK and caspase signaling (2017) · cites this paper as Baker et al, 2011
In the citing paper
“INK-ATTAC mice can be used as a reporter to track the dynamics of p16Ink4a-positive cells.”
From Exercise activates AMPK in mouse and human pancreatic islets to decrease senescence (2024) · cites this paper as [25]
In the citing paper
“Indeed, sub-populations of senescent MuSCs marked by expression of p16Ink4a contribute to sarcopenic wasting and repair dysfunction characteristic of aged muscles in the accelerated-aging BubR1 hypomorphic mouse model59,60.”
From The central role of muscle stem cells in regenerative failure with aging (2015) · cites this paper as [60]
In the citing paper
“Conditional ablation of this p16Ink4a-expressing MuSC population and other senescent cells ameliorates muscle wasting, leading to improved performance in treadmill exercise tests60.”
From The central role of muscle stem cells in regenerative failure with aging (2015) · cites this paper as [60]
In the citing paper
“In animals, genetic and pharmacologic reduction of senescent cell burden results in the prevention, delay, and/or alleviation of a variety of aging-related diseases and sequelae.”
From Reducing Senescent Cell Burden in Aging and Disease (2020) · cites this paper as [3]
In the citing paper
“Senolytics have been used to prevent, delay, or alleviate a plethora of age-onset diseases and syndromes in pre-clinical models.”
From Reducing Senescent Cell Burden in Aging and Disease (2020) · cites this paper as [3]
In the citing paper
“While genetic models of senescent cell clearance provide proof-of-principle for the health and life span benefits of reducing the burden of old cells and the SASP”
From Reducing Senescent Cell Burden in Aging and Disease (2020) · cites this paper as [3]
In the citing paper
“Elimination of even a relatively small proportion of existing senescent cells (~30% reduction) using a “suicide” transgene, INK-ATTAC, that permits inducible elimination of p16Ink4a-expressing senescent cells upon administration of a drug (AP20187; Figure 2), extends healthspan and prevents the development of multiple age-related morbidities in both progeroid and normal chronologically-aged mice [”
From Reducing Senescent Cell Burden in Aging and Disease (2020) · cites this paper as [3]
In the citing paper
“Clearance of senescent cells only late in life did not improve age-related pathologies but did attenuate their progression170.”
From Stem cell aging: mechanisms, regulators and therapeutic opportunities (2014) · cites this paper as [170]
In the citing paper
“Using an inducible genetic model for senescent cell ablation, one study demonstrated that life-long clearance of senescent cells from progeroid mouse tissues, via ablation of p16Ink4a-expressing cells, delays the onset of pathologies in multiple aging tissues, including the fat, muscle and eye170.”
From Stem cell aging: mechanisms, regulators and therapeutic opportunities (2014) · cites this paper as [170]
In the citing paper
“selective killing of those p16-expressing cells in a premature ageing mouse model also delays ageing phenotypes 148”
From Inside and out: the activities of senescence in cancer (2014) · cites this paper as [148]
In the citing paper
“Accordingly, removal of senescent cells by genetic or pharmacological “senolytic” approaches extends median lifespan in old mice and prevents the onset of age-associated disease (Baker et al., 2016; Baker et al., 2011; Xu et al., 2018; Zhu et al., 2015).”
From Cytoplasmic DNA: sources, sensing, and role in aging and disease (2021) · cites this paper as Baker et al., 2011
In the citing paper
“However, senescence has also been implicated both in promoting carcinogenesis 15 and in age-related pathologies 16,17 through its autocrine and paracrine effects, known as the senescence-associated secretory phenotype (SASP) originally described by the Campisi group.18,19”
From Senescence from G2 arrest, revisited (2015) · cites this paper as [16]
In the citing paper
“In support of this tenet, the genetic ablation of p16 + cells in a transgenic mouse model is sufficient to extend the lifespan of naturally aged mice and reduce the manifestation of age-associated pathologies, including cancer.177”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [177]
In the citing paper
“The whole-body elimination of p16 + senescent cells in middle-aged mice reduces the rate of spontaneous tumor formation.177”
From Meta-hallmarks of aging and cancer (2023) · cites this paper as [177]
In the citing paper
“The expression of p16Ink4a is essentially undetectable in young and healthy tissues, but p16Ink4a+ cells accumulate in many aged or diseased tissues.18,19,21,22,23,28”
From Identifying specific functional roles for senescence across cell types (2024) · cites this paper as [22]
In the citing paper
“The expression of p16Ink4a is essentially undetectable in young and healthy tissues, but p16Ink4a+ cells accumulate in many aged or diseased tissues.18,19,21,22,23,28”
From Identifying specific functional roles for senescence across cell types (2024) · cites this paper as [22]
In the citing paper
“Moreover, multiple p16-based mouse models [15,26–28] might not target the same p16high cells in vivo due to different transgene designs (such as different p16 promoters or transgene locations).”
From The heterogeneity of cellular senescence: insights at the single-cell level (2023) · cites this paper as [15]
In the citing paper
“Excessive accumulation of senescent cells in numerous tissues leads to multiple chronic diseases, tissue dysfunction, age-related diseases and organ ageing.”
From Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases (2020) · cites this paper as [13]
In the citing paper
“However, excessive accumulation of senescent cells causally shortens the healthy lifespan [11] and drives organ ageing [12], age-related organ deterioration/disorders [13,14], tissue dysfunction and chronic diseases, including cardiovascular diseases (CVDs) [15,16], cancer [2], neurodegenerative diseases [17,18] and osteoarthritis [19].”
From Immune Clearance of Senescent Cells to Combat Ageing and Chronic Diseases (2020) · cites this paper as [13]
In the citing paper
“mice that express low levels of the spindle assembly checkpoint protein BubR1 (BubR1H/H) exhibit multiple age-related phenotypes at 3–5 months of age, including atrophic skeletal muscle fibers, muscle wasting, and impaired skeletal muscle regeneration”
From Skeletal muscle aging, cellular senescence, and senotherapeutics: current knowledge and future directions (2021) · cites this paper as Baker et al., 2011
In the citing paper
“Exposure to the drug AP20187 causes the caspase 8 fusion protein unique to p16INK4a-expressing cells to dimerize and initiate apoptosis (Baker et al., 2011; Xu et al., 2018).”
From Skeletal muscle aging, cellular senescence, and senotherapeutics: current knowledge and future directions (2021) · cites this paper as Baker et al., 2011
In the citing paper
“Encouragingly, initiation of p16INK4a-postive cell clearance in mid-life also benefitted the molecular and morphological phenotype of skeletal muscle and measures of physical function in progeroid mice.”
From Skeletal muscle aging, cellular senescence, and senotherapeutics: current knowledge and future directions (2021) · cites this paper as Baker et al., 2011
In the citing paper
“Further, muscle fiber size and treadmill exercise time, distance, and total work to exhaustion were significantly greater in AP20187 treated BubR1 H/H;INK-ATTAC mice.”
From Skeletal muscle aging, cellular senescence, and senotherapeutics: current knowledge and future directions (2021) · cites this paper as Baker et al., 2011
In the citing paper
“This model has enabled the study of how systemic removal of p16Ink4a-expressing cells, that are presumably senescent, affect the structure and function of multiple organ systems.”
From Skeletal muscle aging, cellular senescence, and senotherapeutics: current knowledge and future directions (2021) · cites this paper as Baker et al., 2011
In the citing paper
“A major conceptual advance in the role of senescent cells in organismal aging was driven by the development and application of the INK-ATTAC mouse model (Baker et al., 2011).”
From Skeletal muscle aging, cellular senescence, and senotherapeutics: current knowledge and future directions (2021) · cites this paper as Baker et al., 2011
In the citing paper
“In contrast, deletion of senescent cells by a genetic approach attenuated age-related deterioration and extended the health-span in aged mice.8,9”
From Elimination of senescent cells by β-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice (2020) · cites this paper as [8]
In the citing paper
“Senescent cells can impair tissue function in ageing despite their relatively low abundance (< 15%) [3], [4].”
From Iron accumulation in senescent cells is coupled with impaired ferritinophagy and inhibition of ferroptosis (2018) · cites this paper as [4]
In the citing paper
“Importantly, genetic or chemical ablation of senescent cells in mouse models delays the onset of age-related disorders, including cancer, leading to increased life-spans and promoting tissue rejuvenation in late life.36–38”
From Paracrine roles of cellular senescence in promoting tumourigenesis (2018) · cites this paper as [37]
In the citing paper
“Indeed, when senescent cells were removed from aged mice artificially, the animals lived longer and were healthier [96].”
From Evolution of the immune system in humans from infancy to old age (2015) · cites this paper as [96]
Citations
Cites
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477 · cited 1×
“After 48 h, cultures were fixed and stained for SA-b-Gal activity as describe”
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Four faces of cellular senescence
Rodier, F., & Campisi, J. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201009094 · Cited by 2,070
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Senescence of Activated Stellate Cells Limits Liver Fibrosis
Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027 · cited 1×
“There were no overt side effects of senescent cell clearance in our model, even though it has been postulated that senescent cells enhance certain types of tissue repai”
Ink4a/Arf expression is a biomarker of aging
Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L., & Sharpless, N. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22475 · Cited by 1,486 · cited 1×
“Additionally, the expression of p16 Ink4a is known to increase with ageing in several rodent and human tissue”
The Regulation of INK4/ARF in Cancer and Aging
Kim, W. Y., & Sharpless, N. E. (2006) · Cell · doi:10.1016/j.cell.2006.10.003 · Cited by 1,009
Jun, J.-I., & Lau, L. F. (2010) · Nature Cell Biology · doi:10.1038/ncb2070 · Cited by 998 · cited 1×
“There were no overt side effects of senescent cell clearance in our model, even though it has been postulated that senescent cells enhance certain types of tissue repai”
A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow
Soleimani, M., & Nadri, S. (2009) · Nature Protocols · doi:10.1038/nprot.2008.221 · Cited by 920 · cited 1×
“Cell culture Culture of bone marrow cells was as previously describe”
Cited by
Sorted by citations
Items 2,201–2,300 of 3,753
Yu, Y. C.-Y., Hui, T., Kao, T.-H., Liao, H., Yang, C.-Y., Hou, C., Hsieh, H.-T., Chang, J., Tsai, Y., Pinskaya, M., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00103 · Cited by 16
“Emerging studies suggest the elimination of senescent cells to extend the healthspan (Baker et al., 2011, 2016; Xu et al., 2015; Palmer et al., 2019).”
BackgroundTran, K. A., Gilbert, M., Vazquez, B. N., Ianni, A., Garcia, B. A., Vaquero, A., & Berger, S. L. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.05.025 · Cited by 15
Brondello, J., Prieur, A., Philipot, D., Lemaı̂tre, J.-M., Lenaers, G., Piette, J., & Dulić, V. (2012) · médecine/sciences · doi:10.1051/medsci/2012283017 · Cited by 28
“Un autre acteur important dans l’activation de pRb lors de la sénescence est p16Ink4A (p16), un inhibiteur des kinases CDK4/6 (Figure 1) qui, à l’instar de la -galactosidase, est un marqueur bona fide de la sénescence in vitro et in vivo [12, 13].”
BackgroundZhu, J., & Yang, G. (2021) · Nitric Oxide · doi:10.1016/j.niox.2021.08.004 · Cited by 15
Martinović, A., Mantovani, M., Trpchevska, N., Novak, E., Milev, N. B., Bode, L., Ewald, C. Y., Bischof, E. Y., Reichmuth, T., Lapides, R. A., et al. (2024) · Frontiers in Aging · doi:10.3389/fragi.2024.1495029 · Cited by 19
Adipose tissue senescence: Biological changes, hallmarks and therapeutic approaches
Zhang, Y., Jiang, Y., Yang, X., Huang, Y., Pan, A., & Liao, Y. (2024) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2024.111988 · Cited by 17
Johmura, Y., Yamashita, E., Shimada, M., Nakanishi, K., & Nakanishi, M. (2016) · Scientific Reports · doi:10.1038/srep31194 · Cited by 14
“In this regards, recent reports suggest that accumulation of p16 positive cells in body accelerated age-related changes 36 and limits healthy lifespan 37 .”
BRE plays an essential role in preventing replicative and DNA damage-induced premature senescence
Shi, W., Tang, F. M. K., Yao, Y., Tang, C., Chui, Y., & Lee, K. K. (2016) · Scientific Reports · doi:10.1038/srep23506 · Cited by 15
Recent Advances in Senolysis for Age-Related Diseases
Aratani, S., & Nakanishi, M. (2023) · Physiology · doi:10.1152/physiol.00003.2023 · Cited by 16
Synergistic Anti-Ageing through Senescent Cells Specific Reprogramming
Chen, R., & Skutella, T. (2022) · Cells · doi:10.3390/cells11050830 · Cited by 15
“In INK-ATTAC mice, where senescent cells expressing p16INK4A are specifically killed, the loss of senescent cells increases the lifespan and health span [60].”
BackgroundDNA damage in protective and adverse inflammatory responses: Friend of foe?
Poliezhaieva, T., & Ermolaeva, M. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.06.004 · Cited by 15
Ho, C. Y., Wu, M., Thammaphet, J., Ahmad, S., James Ho, C. S., Draganova, L., Anderson, G., Jonnalagadda, U. S., Hayward, R., Shroff, R. C., et al. (2025) · Circulation Research · doi:10.1161/circresaha.124.325374 · Cited by 17
“4,73,74 Our data suggests that capturing or modifying primed cells during presenescence may also be beneficial and that PLA–expressing cells may represent this primed population.”
Shafqat, A., Masters, M. C., Tripathi, U., Tchkonia, T., Kirkland, J. L., & Hashmi, S. K. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102400 · Cited by 15
Self-citationP38-Mediated Cellular Senescence in Conjunctivochalasis Fibroblasts
Xiang, M., Mo, L., Zhan, Y., Wen, H., Zhou, H., & Miao, W. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.19-27617 · Cited by 15
Sun, P., Hu, Y., Xing, Q., Deng, W., Ou, Y., Pan, G., Zhong, X., & Hu, W. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00073 · Cited by 15
Genetic rejuvenation of old muscle
Li, M., & Belmonte, J. C. I. (2014) · Nature · doi:10.1038/nature13058 · Cited by 13
The Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity
Jain, S. S., Sojo, G. B., Sun, H., Friedland, B. N., McNamara, M. E., Schmidt, M. O., & Wellstein, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137013 · Cited by 17
Senescent Cells in IPF: Locked in Repair?
Meiners, S., & Lehmann, M. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2020.606330 · Cited by 14
Çobanoglu, Ö., Delval, L., Ferrari, D. P., Deruyter, L., Heumel, S., Wolowczuk, I., Hussein, A., Menevse, A. N., Bernard, D., Beckhove, P., et al. (2023) · Aging Cell · doi:10.1111/acel.14007 · Cited by 12
Pharmaceutical Intervention of Aging
Qian, M., & Liu, B. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1117-8_15 · Cited by 17
Kitada, K., Nakano, D., Hitomi, H., Kobori, H., Deguchi, K., Mori, H., Masaki, T., & Nishiyama, A. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2012.12001.x · Cited by 14
“Recent advances in technology, such as drug-induced removal of CDKI-positive cells developed by Baker et al.8 may enable this issue to be examined in future studies.”
BackgroundInfluentialGarcía–Martínez, J., Bakker, B., Schukken, K. M., Simon, J. E., & Foijer, F. (2016) · World Journal of Stem Cells · doi:10.4252/wjsc.v8.i6.216 · Cited by 16
Hwang, H. V., Lin, Y., Rebuffatti, M., Tran, D., Lee, L., Gomes, A. V., Li, C., & Knowlton, A. A. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00318.2018 · Cited by 14
Wang, Z., Wei, L. T., Chen, C., Dai, Q., Liu, Z., Liu, J., Zhang, Y., Zhou, M., & Wang, X. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112810 · Cited by 14
Wiley, L., Ashok, D., Martin-Ruiz, C. M., Talbot, D. C. S., Collerton, J. C., Kingston, A., Davies, K., Chinnery, P. F., Catt, M., Jagger, C., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091005 · Cited by 15
Giovos, G., Yavropoulou, M. P., & Yovos, J. G. (2019) · HORMONES · doi:10.1007/s42000-019-00132-6 · Cited by 16
National Institute on Aging at Middle Age—Its Past, Present, and Future
Nagy, C., Bernard, M., & Hodes, R. J. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03994.x · Cited by 16
“For example, the recent discovery that removal of senescent cells—which normally accumulate with age—delays the onset of aging-related dysfunctions opens new avenues for interventions to improve health in elderly adults.(14) Basic research in model organisms has also shown consistently that interventions extending the…”
BackgroundGlucose Metabolism and Aging of Hematopoietic Stem and Progenitor Cells
Poisa-Beiro, L., Landry, J. J. M., Raffel, S., Tanaka, M., Zaugg, J. B., Gavin, A., & Ho, A. D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063028 · Cited by 14
“In animal models, genetic ablation of senescent cells (p16Ink4a-expressing cells) by activating a drug-inducible pro-apoptotic gene has been shown to attenuate the onset of age-related pathologies of progeroid mice [24].”
BackgroundInfluentialSalazar-Terreros, M. J., & Vernot, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137350 · Cited by 15
Advances in Nanotherapy for Targeting Senescent Cells
Shi, Y., Zhang, Y., Zhang, Y., Yao, J., Guo, J., Xu, X., & Wang, L. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s469110 · Cited by 20
Mavrogonatou, E., & Kletsas, D. (2024) · Metabolites · doi:10.3390/metabo14030146 · Cited by 16
“…by the studies of Baker et al., in which the use of the transgene INK-ATTAC for inducible elimination of p16 INK4a -positive senescent cells delayed the onset or attenuated the progression of already established age-related phenotypes in several tissues and extended median lifespan in mice [33,34].”
ResultPermissive role of vascular endothelium in fibrosis: focus on the kidney
Goligorsky, M. S. (2024) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00526.2023 · Cited by 15
Senotherapy, cancer, and aging
Balducci, L., Falandry, C., & Monfardini, S. (2023) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2023.101671 · Cited by 16
Signs of Similarities and Differences in Cellular Models of Aging: A Scoping Review
Васильевна, М. Г., & Khokhlov, A. N. (2022) · Moscow University Biological Sciences Bulletin · doi:10.3103/s0096392522030087 · Cited by 14
“The use of senotherapy in mice improves the endurance of muscles, which consist mostly of terminally differentiated myocytes [43, 44].”
BackgroundAnalysis of the senescence‐associated cell surfaceome reveals potential senotherapeutic targets
Deng, Y., Liu, T., Scifo, E., Li, T., Xie, K., Taschler, B., Morsy, S., Schaaf, K., Ehninger, A., Bano, D., et al. (2024) · Aging Cell · doi:10.1111/acel.14312 · Cited by 15
Kitada, K., Nakano, D., Hitomi, H., Kobori, H., Deguchi, K., Mori, H., Masaki, T., & Nishiyama, A. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12001 · Cited by 14
Mocchegiani, E., & Malavolta, M. (2019) · Springer eBooks · doi:10.1007/978-3-319-99375-1_66 · Cited by 15
Song, H.-D., Kim, S. N., Saha, A., Ahn, S.-Y., Akindehin, S., Son, Y., Cho, Y. K., Kim, M., Park, J.-H., Jung, Y.-S., et al. (2020) · Aging and disease · doi:10.14336/ad.2019.0810 · Cited by 14
“Aging and Disease • Volume 11, Number 3, June 2020 576 be beneficial for delaying age-related disorders and increasing life span [9].”
BackgroundThe Potent and Paradoxical Biology of Cellular Senescence in Cancer
Romesser, P. B., & Lowe, S. W. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-124434 · Cited by 15
Aging and the Krüppel-like factors.
Hsieh, P. N., Sweet, D. R., Fan, L., & Jain, M. K. (2017) · PubMed · Cited by 15
Peeper, D. S. (2011) · Nature · doi:10.1038/479186a · Cited by 14
Circular RNA-based protein replacement therapy mitigates osteoarthritis in male mice
Suo, J., Li, L., Tan, W., Yin, X., Wang, J., Shao, R., Sun, S., Guo, S.-K., Feng, J., Gao, B., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63343-z · Cited by 15
“Disruptions from aging 30 , injury/in fl ammation 31 and metabolic changes 32 shift this balance, leading to ECM breakdown marked by decreased collagen type II (COL2) and aggrecan alongside elevated matrix metalloproteinase 13 (MMP13) and a disintegrin and metalloproteinase with thrombos-pondin…”
Perillo, M., Punzo, A., Caliceti, C., Sell, C., & Lorenzini, A. (2023) · Biomedical Journal · doi:10.1016/j.bj.2023.100596 · Cited by 14
“[2] Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, et al.”
BackgroundAgeing-associated phenotypes in mice
Xie, K., & Ehninger, D. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111852 · Cited by 14
p19Arf Exacerbates Cigarette Smoke-Induced Pulmonary Dysfunction
Mikawa, R., Sato, T., Suzuki, Y., Baskoro, H., Kawaguchi, K., & Sugimoto, M. (2020) · Biomolecules · doi:10.3390/biom10030462 · Cited by 14
Zhang, K., Chen, C., Liu, Y., Chen, H., & Liu, J. (2014) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12328 · Cited by 14
“Eliminating the cyclin-dependent protein kinase inhibitor p16 positive senescent cells from the tissues delays age-related dysfunction tissue ageing.(31) Silencing p16 in geriatric muscle satellite cells restores the ageing-dependent decline of the stem cell muscle regenerative functions.”
BackgroundZhou, D., Yin, D., Xiao, F., & Hao, J. (2015) · Medical Science Monitor · doi:10.12659/msm.895596 · Cited by 14
“Consistent with our hypothesis, a positive association between accelerated senescence and cataract formation was identified in BubR1 hypomorphic mice and discard of p16Ink4a, which may significantly postpone the appearance of cataracts in mice [21,22].”
BackgroundTranscriptomic markers of biological aging in breast cancer survivors: a longitudinal study
Carroll, J., Crespi, C. M., Cole, S., Ganz, P. A., Petersen, L., & Bower, J. E. (2024) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djae201 · Cited by 16
Mu, X., Lin, C.-Y., Hambright, W. S., Tang, Y. M., Ravuri, S. K., Lu, A., Matre, P. R., Chen, W., Gao, X., Cui, Y., et al. (2020) · Aging · doi:10.18632/aging.202413 · Cited by 14
Galactose-modified duocarmycin prodrugs as senolytics
(2019) · doi:10.1101/746669 · Cited by 172
Cell Senescence, Telomerase, and Senolytic Therapy
Fossel, M. (2019) · OBM Geriatrics · doi:10.21926/obm.geriatr.1901034 · Cited by 14
Brown, A. A., Ding, Z., Viñuela, A., Glass, D., Parts, L., Spector, T. D., Winn, J. M., & Durbin, R. M. (2015) · G3 Genes Genomes Genetics · doi:10.1534/g3.114.011411 · Cited by 12
“For example, cellular senescence, when a cell loses the ability to divide, can form a break on cancer development, and clearing such senescent cells can delay the development of age-associated disorders [Baker et al., 2011].”
BackgroundMitochondria in cell senescence: A Friend or Foe?
Chen, Q., Young, L. H., & Barsotti, R. (2023) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2023.02.019 · Cited by 15
Contribution of BubR1 to oxidative stress‐induced aneuploidy in p53‐deficient cells
Ikawa‐Yoshida, A., Ando, K., Oki, E., Saeki, H., Kumashiro, R., Taketani, K., Ida, S., Tokunaga, E., Kitao, H., Morita, M., et al. (2013) · Cancer Medicine · doi:10.1002/cam4.101 · Cited by 13
“[42], who demonstrated that the reduction in BubR1 levels causes cell senescence by activating the p16Ink4a–Rb signaling pathway in a mouse model.”
Tun, X., Wang, E. J., Gao, Z., Lundberg, K. C., Xu, R., & Hu, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065697 · Cited by 14
“, AD, senescent cells accumulate during disease progression and induce severe SASPs, causing inflammatory responses, cytokine accumulation, and increased reactive oxygen species which degenerate tissue [21].”
BackgroundThe InflammTORy Powers of Senescence
Serrano, M. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.09.011 · Cited by 14
Sharma, G., Banerjee, R., & Srivastava, S. (2023) · ACS Omega · doi:10.1021/acsomega.3c07480 · Cited by 13
Rejuvenating Muscle Stem Cell Function: Restoring Quiescence and Overcoming Senescence
Mendelsohn, A. R., & Larrick, J. W. (2016) · Rejuvenation Research · doi:10.1089/rej.2016.1829 · Cited by 14
“There are studies that indicate that targeted destruction of p16ink4a expressing cells extends life- and health-span or confers other anti-aging benefits [20] [21] [22] [23] [24].”
BackgroundConover, C. A., & Bale, L. K. (2022) · Experimental Gerontology · doi:10.1016/j.exger.2022.112070 · Cited by 14
Yang, Y., Duan, C., Huang, L., Xia, X., Zhong, Z., Wang, B., Wang, Y., & Ding, W. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112838 · Cited by 13
Killing wisely: precision senolytics in the age of frailty
Barthet, V. J. A., & Lowe, S. W. (2025) · Genes & Development · doi:10.1101/gad.353134.125 · Cited by 13
“Indeed, in-depth molecular characterization of various senescence contexts has un-covered distinct senescent subtypes with varying SASP composition, metabolic and immune interactions (Coppé et al. 2010; Baker et al. 2011; Zhu et al. 2015; Yosef et al. 2016; Childs et al. 2017; Xu et al. 2018).”
Bahour, N., Bleichmar, L., Abarca, C., Wilmann, E., Sanjines, S., & Aguayo‐Mazzucato, C. (2023) · Aging · doi:10.18632/aging.204483 · Cited by 13
Longevity with Systems Medicine? Epigenome, Genome and Environment Interactions Network
Roukos, D. H. (2012) · Epigenomics · doi:10.2217/epi.12.1 · Cited by 13
Wnuk, M., Sol‐Fernández, S. D., Błoniarz, D., Słaby, J., Szmatoła, T., Żebrowski, M., Martínez‐Vicente, P., Litwinienko, G., Moros, M., & Lewińska, A. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00771 · Cited by 13
Shinde, P., Kuhikar, R., Kulkarni, R. S., Khan, N., Limaye, L. S., & Kale, V. P. (2021) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.3180 · Cited by 13
Gellert‐Kristensen, H., Bojesen, S. E., Hansen, A. T., & Stender, S. (2023) · Hepatology · doi:10.1097/hep.0000000000000608 · Cited by 13
“[6] Genetic mutations that disrupt normal telomere function have medical consequences in humans.”
BackgroundThe eroding chromatin landscape of aging stem cells
Shi, C., Wang, L., & Sen, P. (2020) · Translational Medicine of Aging · doi:10.1016/j.tma.2020.08.002 · Cited by 14
Odama, M., Maegawa, E., Suzuki, K., Fujii, Y., Maeda, R., Murakami, S., & Ito, T. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.2c08563 · Cited by 12
Li, Y., Zhang, C., Cheng, H., Lv, L., Zhu, X., Ma, M., Xu, Z., He, J., Xie, Y., Yang, X., et al. (2024) · Experimental Gerontology · doi:10.1016/j.exger.2024.112522 · Cited by 13
“The removal of senescent cells can prevent or delay tissue dysfunction and prolong healthy life (Baker et al., 2011).”
BackgroundExamining how p16INK4a expression levels are linked to handgrip strength in the elderly
Kao, T., Chen, W., Han, D., Huang, Y.-H., Chen, C., & Yang, W. (2016) · Scientific Reports · doi:10.1038/srep31905 · Cited by 13
Zhang, Y., Shao, C., Li, H., Wu, K., Gong, L., Zheng, Q., Dan, J., Jia, S., Tang, X., Wu, X., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.597566 · Cited by 13
“Late-life clearance also attenuated the progression of already established age-related disorders (Baker et al., 2011).”
BackgroundAdult progenitor rejuvenation with embryonic factors
Wang, P., Liu, X., Chen, Y., Jun‐Hao, E. T., Yao, Z., Min‐Wen, J. C., Chua, B. Y.-J., Ma, S., Ma, W., Luo, L., et al. (2023) · Cell Proliferation · doi:10.1111/cpr.13459 · Cited by 13
Rossi, C., Venturin, M., Gubała, J., Frasca, A., Corsini, A., Battaglia, C., & Bellosta, S. (2023) · Biomedicines · doi:10.3390/biomedicines11123228 · Cited by 14
“Cell senescence could be targeted to prevent or delay the aging process and tissue dysfunction extending lifespan [75,76].”
BackgroundIkawa‐Yoshida, A., Matsumoto, T., Okano, S., Aoyagi, Y., Matsubara, Y., Furuyama, T., Nakatsu, Y., Tsuzuki, T., Onimaru, M., Ohkusa, T., et al. (2016) · Scientific Reports · doi:10.1038/srep32399 · Cited by 13
Lactose induced redox-dependent senescence and activated Nrf2 pathway.
Xing, S., Zhang, L., Lin, H., Mao, Z., Bao, K., Peng, H. F., Pei, Z., Li, J., & Hu, Z. (2019) · Europe PMC (PubMed Central) · Cited by 11
Therapeutic Potential and Clinical Effectiveness of Quercetin: A Dietary Supplement
Devi, V., Deswal, G., Dass, R., Chopra, B., Kriplani, P., Grewal, A. S., Guarve, K., & Dhingra, A. K. (2024) · Recent Advances in Food Nutrition & Agriculture · doi:10.2174/012772574x269376231107095831 · Cited by 13
The influence of photodynamic therapy with 5-aminolevulinic acid on senescent skin cancer cells
Grigalavicius, M., Juraleviciute, M., Kwitniewski, M., & Juzeniene, A. (2016) · Photodiagnosis and Photodynamic Therapy · doi:10.1016/j.pdpdt.2016.10.008 · Cited by 14
“It has been demonstrated both in vitro and in vivo that clearance of senescent cells delays ageingassociated disorders [8].”
BackgroundMalojirao, V. H., Vasquez, V., Kodavati, M., Mitra, J., Provasek, V., Voh, A. T. T., Liopo, A. V., Derry, P. J., Mikheev, A. M., Rostomily, R. C., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-07983-3 · Cited by 13
Sarad, K., Jankowska, U., Skupień-Rabian, B., Babler, A., Kramann, R., Dulak, J., & Jaźwa, A. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-05028-7 · Cited by 13
“Clearance of senescent cells with either genetic or pharmacologic approaches was shown to delay or inhibit several age-associated disorders in mice [34].”
Telomere dysfunction in chronic liver disease: The link from aging
Penrice, D. D., Jalan‐Sakrikar, N., Jurk, D., Passos, J. F., & Simonetto, D. A. (2023) · Hepatology · doi:10.1097/hep.0000000000000426 · Cited by 14
“[57,58] Mitochondrial dysfunction can also release mtDNA, which can activate the cyclic GMP-AMP synthase/stimulator of interferon genes pathway system, thereby inciting the immune and inflammatory responses.”
Uncoupling of mTORC1 from E2F activity maintains DNA damage and senescence
Daigh, L. H., Saha, D., Rosenthal, D. L., Ferrick, K. R., & Meyer, T. (2024) · Nature Communications · doi:10.1038/s41467-024-52820-6 · Cited by 16
“The role of p16 in triggering senescence is relevant in vivo since expression of the tumor suppressor p16 is a molecular hallmark of senescent cells 2,23 and p16-positive senescent cells play a causative role in multiple aging-associated phenotypes 24,25 .”
Yang, H. H., Zhang, H., Son, J., & Kim, J. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0577-8 · Cited by 13
Lu, X., Wu, J., Agborbesong, E., & Li, X. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02650-2 · Cited by 19
“It has been reported that purging p16-positive senescent cells in INK-ATTAC mice, a transgenic mouse model that allowed the removal of p16 Ink4a -positive cells upon administration of a drug, AP20187, increased mean lifespan [9].”
InfluentialApplications of nanodiamonds in the diagnosis and treatment of neurological diseases
Tang, G. F., Zhang, M. R., Liu, Q., Tian, X., & R., R. (2022) · Journal of Nanoparticle Research · doi:10.1007/s11051-022-05434-2 · Cited by 13
“At present, the most convincing antiaging treatment comes from a complex experiment that genetically modified a mouse model of progeria BubR1 and used drug therapy to activate the INK-ATTAC transgene to eliminate P16INK4A senescent cells, significantly delaying age-related diseases (Baker et al. 2011).”
BackgroundDrullion, C., Marot, G., Martin, N., Deslé, J., Saas, L., Salazar-Cardozo, C., Bouali, F., Pourtier, A., Abbadie, C., & Pluquet, O. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.008 · Cited by 13
Mitochondrial Membrane Disrupting Molecules for Selective Killing of Senescent Cells
Jana, B., Kim, S., Chae, J., Chung, H., Kim, C., & Ryu, J. (2021) · ChemBioChem · doi:10.1002/cbic.202100412 · Cited by 13
New Insights for BPIFB4 in Cardiovascular Therapy
Dossena, M., Ferrario, A., Lopardo, V., Ciaglia, E., & Puca, A. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197163 · Cited by 12
Senescent cell removal via JAG1‐NOTCH1 signalling in the epidermis
Yoshioka, H., Yamada, T., Hasegawa, S., Miyachi, K., Ishii, Y., Hasebe, Y., Inoue, Y., Tanaka, H., Iwata, Y., Arima, M., et al. (2021) · Experimental Dermatology · doi:10.1111/exd.14361 · Cited by 13
Cellular uptake and retention studies of silica nanoparticles utilizing senescent fibroblasts
Perrigue, P. M., Henschke, A., Grześkowiak, B. F., Przysiecka, Ł., Jaskot, K., Mielcarek, A., Coy, E. L., & Moya, S. E. (2023) · Scientific Reports · doi:10.1038/s41598-022-26979-1 · Cited by 15
The Aging Microenvironment Shapes Alveolar Macrophage Identity in AgingPreprint
McQuattie‐Pimentel, A. C., Ren, Z., Joshi, N., Watanabe, S., Stoeger, T., Chi, M., Lu, Z., Sichizya, L., Aillon, R. P., Chen, C.-I., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/717033 · Cited by 13
“These findings have implications for therapy–senolytic or other novel therapies might indirectly target the immune dysfunction during aging through effects on the lung parenchyma (Baker et al., 2011; Jeon et al., 2017).”
BackgroundMechanisms of cellular senescence-induced vascular aging: evidence of senotherapeutic strategies
Mahoney, S. A., Bloom, S. I., Seals, D. R., Donato, A. J., Rossman, M. J., & Clayton, Z. S. (2025) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2024.31 · Cited by 15
“However, the accumulation of senescent cells and the SASP has been implicated in various age-related pathologies, including CVD [33– 35] .”
New Directions in Research on Aging
Bartke, A. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-021-10305-9 · Cited by 15
Elucidating Proteoform Dynamics Underlying the Senescence Associated Secretory Phenotype
Doubleday, P. F., Fornelli, L., & Kelleher, N. L. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00739 · Cited by 14
Seno-suppressive molecules as new therapeutic perspectives in rheumatic diseases
Tachikart, Y., Malaise, O., Mumme, M., Jørgensen, C., & Brondello, J. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.017 · Cited by 12
Cellular Senescence Exacerbates Features of Aging in the Eyes
Kitazawa, K., Campisi, J., Numa, K., Patel, S. K., King, C. D., Matsumoto, A., Sotozono, C., Desprez, P., & Schilling, B. (2023) · doi:10.59368/agingbio.20230014 · Cited by 13
Senotherapeutics: An emerging approach to the treatment of viral infectious diseases in the elderly
Li, Z., Tian, M., Wang, G., Cui, X., Ma, J., Liu, S., Shen, B., Liu, F., Wu, K., Xiao, X., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1098712 · Cited by 13
“p21 and p16 maintain the tumor suppressor protein pRb in an inactive hypophosphorylated state, thereby preventing the transcription factor E2F from transcribing genes that promote cell cycle progression, and both are often used as unique senescence hallmarks to identify senescent cells in tissues and cultured cells (N…”
BackgroundAifuwa, I., Kim, B. C., Kamat, P., Starich, B., Agrawal, A., Tanrioven, D., Luperchio, T. R., Valencia, A. M. J., Perestrelo, T., Reddy, K. L., et al. (2022) · PNAS Nexus · doi:10.1093/pnasnexus/pgac270 · Cited by 12
“The accumulation of senescent cells within aging tissues results in tissue dysfunctions (11, 12) that in part stem from soluble factors secreted by senescent cells, termed senescence-associated secretory phenotype (SASP)(7).”
BackgroundYamaguchi, Y., Zampino, M., Tanaka, T., Bandinelli, S., Osawa, Y., Ferrucci, L., & Semba, R. D. (2020) · The Journals of Gerontology Series A · doi:10.1093/gerona/glaa324 · Cited by 11
Metadata
- Authors
- Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M.
- Affiliations
- Mayo Clinic (US)
- ORCID
- Venue
- Nature
- Published
- 2011-11
- Volume
- 479
- Issue
- 7372
- Pages
- 232-236
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3468323
- OpenAlex
- W2069519394
- Cited by
- 3,670
- References
- 32
- Citations by year
- 2026: 221 · 2025: 284 · 2024: 347 · 2023: 316 · 2022: 333 · 2021: 333 · 2020: 324 · 2019: 299 · 2018: 250 · 2017: 190 · 2016: 203 · 2015: 157 · 2014: 159 · 2013: 127 · 2012: 119
- FWCI
- 89.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- PubMed Central (acceptedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- National Institute on Aging (P01AG041122, AG 13925, R01AG013925, R37AG013925)
- National Cancer Institute (CA-96985, R01CA096985)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK050456)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Keywords
- cellular senescence, senolytics, senolytic therapy, p16INK4a, senescent cell clearance, aging, age-related diseases, healthspan extension, adipose tissue, skeletal muscle, eye, tissue dysfunction
- MeSH terms
- Adipose Tissue, Aging, Animals, Bone Marrow Cells, Cell Count, Cells, Cultured, Eye, Female, Genotype, Longevity, Male, Mice, Transgenic, Phenotype, Progeria, Time Factors, Weaning, Gene Expression, Tacrolimus, Cellular Senescence, Protein Serine-Threonine Kinases, Muscle, Skeletal, Cell Cycle Proteins, Cyclin-Dependent Kinase Inhibitor p16, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
